Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs

1. Z. Hlinak, J. Vinsova and E. Kasafirek, Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice, Eur. J. Pharmacol.314 (1996) 1–7.10.1016/S0014-2999(96)00485-2Search in Google Scholar

2. Z. Hlinak and I. Krejci, Oxiracetam pre-but not post-treatment prevented social recognition deficits produced with trimethyltin in rats, Behav. Brain Res.161 (2005) 213–219; DOI: 10.1016/j.bbr.2005.02.030.10.1016/j.bbr.2005.02.030Search in Google Scholar

3. C. Mondadori, B. Hengerer, T. Ducret and J. Borkowski, Delayed emergence of effects of memoryenhancing drugs: implications for the dynamics of long-term memory, Proc. Natl. Acad. Sci. USA91 (1994) 2041–2045.10.1073/pnas.91.6.2041Search in Google Scholar

4. C. Mondadori, H. J. Möbius and J. Borkowski, The GABAB receptor antagonist CGP 36,742 and the nootropic oxiracetam facilitate the formation of long-term memory, Behav. Brain Res. 77 (1996) 223–225.10.1016/0166-4328(95)00222-7Search in Google Scholar

5. W. H. Brooks, W. C. Guida and K. G. Daniel, The significance of chirality in drug design and development, Curr. Top. Med. Chem. 11 (2011) 760–770; DOI: 10.2174/156802611795165098.10.2174/156802611795165098Search in Google Scholar

6. A. J. Hutt, Chirality and pharmacokinetics: an area of neglected dimensionality, Drug Metabol. Drug Interact. 22 (2007) 79–112; DOI: 10.1515/DMDI.2007.22.2-3.79.10.1515/DMDI.2007.22.2-3.79Search in Google Scholar

7. T. Kolev, M. Spiteller and B. Koleva, Spectroscopic and structural elucidation of amino acid derivatives and small peptides: experimental and theoretical tools, Amino Acids38 (2010) 45–50; DOI: 10.1007/s00726-008-0220-9.10.1007/s00726-008-0220-9Search in Google Scholar

8. H. Lu, Stereoselectivity in drug metabolism, Expert Opin. Drug Metab. Toxicol. 3 (2007) 149–158; DOI: 10.1517/17425255.3.2.149.10.1517/17425255.3.2.149Search in Google Scholar

9. Q. Shen, L. Wang, H. Zhou, L. S. Yu and S. Zeng, Stereoselective binding of chiral drugs to plasma proteins, Acta Pharmacol. Sinica34 (2013) 998–1006; DOI: 10.1038/aps.2013.78.10.1038/aps.2013.78Search in Google Scholar

10. N. Inotsume and M. Nakano, Stereoselective determination and pharmaco-kinetics of dihydropyridines: an updated review, J. Biochem. Biophys. Methods54 (2002) 255–274; DOI: 10.1016/S0165-022X(02)00120-3.10.1016/S0165-022X(02)00120-3Search in Google Scholar

11. R. Mehvar and D. R. Brocks, Stereospecific pharmacokinetics and pharmacodynamics of betaadrenergic blockers in humans, J. Pharm. Pharm. Sci. 4 (2001) 185–200.Search in Google Scholar

12. L.A. Nguyen, H. He and C. Pham-Huy, Chiral drugs: an overview, Int. J. Biomed. Sci.2 (2006) 85–100.Search in Google Scholar

13. L. Chiodini, G. Pepeu, Composition Comprising S-oxiracetame for Use as Nootropic, EP. WO 1,993,006,826 A1, 15 April 1993; ref. Chem. Abstr. 119 (1993) 139083.Search in Google Scholar

14. W. S. Wang, H. Ji, H. T. Xie, M. Dai, Y. W. Jia, D. H. Liang, L. Ye and Z. Y. Rong, A sensitive and specific UPLC–MS/MS analysis and preliminary pharmacokinetic characterization of S-oxiracetam in beagle dogs, Chin. J. Clin. Pharmacol Ther. 17 (2012) 988–994.Search in Google Scholar

15. J. B. Lecaillon, J. P. Dubois, H. Coppens, T. Darragon, W. Theobald, G. Reumond and H. Beck, Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with nongeriatric healthy subjects, Eur. J. Drug Metab. Pharmacokinet.15 (1990) 223–237.10.1007/BF031902082253653Search in Google Scholar

16. E. Perucca, A. Albrici, G. Gatti, R. Spalluto, M. Visconti and A. Crema, Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers, Eur. J. Drug Metab. Pharmacokinet. 9 (1984) 267–274.10.1007/BF031896506519128Search in Google Scholar

17. E. Perucca, J. Parini, A. Albrici, M. Visconti and E. Ferrero, Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly, Eur. J. Drug Metab. Pharmacokinet.12 (1987) 145148.Search in Google Scholar

18. X. Wan, H. Wang, P. Ma, L. Xi, J. Sun, Z. He, X. Zhang and X. Liu, Simultaneous determination of oxiracetam and its degraded substance in rat plasma by HPLC–MS/MS and its application to pharmacokinetic study after a single high-dose intravenous administration, J. Chromatogr. B. 969 (2014) 95–100; DOI: 10.1016/j.jchromb.2014.07.041.10.1016/j.jchromb.2014.07.04125168792Search in Google Scholar